Search Telecare Aware
Like it? Share it!
 |
|
 |
 |
 |
 |
 |
sponsorship banners general advertising *special: sponsor a conference report* |
3 Febuary edition of the Telemedicine Reporter International Edition (PDF) for download thanks to US Tele-Medicine. To be emailed when the next is released email their media dept. |
|
| The gist is...If you have a serious comment to make anonymously...email it, don't just post it. |
Truly anonymous comments - where the writer is unknown - are not published unless they are unexceptional.
Comments or articles where the authorship is known but are offered for publication anonymously are considered on their merits. (Email Steve or Donna in confidence.) There are some circumstances where it is necessary to be close to a particular situation to be able to throw light on it but to write about it publicly would jeopardise the author's position. In that case, the decision to publish an item anonymously hinges on the question of whether or not it is informed opinion that will add insight to, or might start, a debate on a particular topic.
Unsubstantiated allegations of illegal behaviour or substandard products, for example, would not be posted unless they could be independently verified, in which case we would probably publish them ourselves.
Just because a post, article or comment, etc. is published on Telecare Aware readers cannot and should not infer that the editors agree with the author, anonymous or not.
Steve Hards
Donna Cusano
Editors
steve.hards@telecareaware.com
donna.cusano@telecareaware.com
Pharma comparison ... |
| Monday, 23 August 2010 18:36 |
|
John S, I agree with you that Tunstall should not have to run their business in a charitable way. However there is a major difference in the pharma sector currently to that of Telecare. Pharma suppliers have for many years sustained extremely high development costs to bring each drug to market; partly in demonstrating the safety of each drug. So perhaps reasonable for them to take high profits? More recently, because this cost means drugs are not being readily produced for third world countries where treatable diseases kill all too readily, academia has stepped in - pre-development work using non laboratory time (through data mining and bioinformatics analysis and prediction techniques) has seen the pharma sector work in partnership with academia to develop 'cheaper' (relatively) drugs. Since we do not have such stringent safety issues for Telecare equipment it is unlikely that the status quo will change; consequently companies will either develop and market their own solutions or they will let someone do the development and then buy them out and take the profit from the marketing. Both approaches carry risk ... but that is part of business and part of life? If the products and services stand up to scrutiny and serve the intend purpose we should expect to pay the market rate. |
